Regeneron Pharmaceuticals (NASDAQ:REGN) should head towards $489.94 per share according to 18 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $325 per share. The higher price estimate target is at $668 according to the Analysts.
Many analysts have stated their opinion on the company shares. In a research note released to the investors, Wells Fargo downgrades its rating on Regeneron Pharmaceuticals (NASDAQ:REGN).The analysts at the brokerage house have a current rating of Market Perform on the shares. Earlier, the shares were rated a Outperform by the brokerage firm. The rating by the firm was issued on April 20, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Ryan Arthur F, director of Regeneron Pharmaceuticals Inc, had unloaded 1,000 shares at an average price of $396.64 in a transaction dated on May 24, 2016. The total value of the transaction was worth $396,640.
Regeneron Pharmaceuticals (NASDAQ:REGN) stock ended Monday session in the red zone in a volatile trading. The stock closed down 4.8 points or 1.29% at $367.23 with 855,728 shares getting traded. Post opening the session at $371.71, the shares hit an intraday low of $366.9 and an intraday high of $375.3799 and the price was in this range throughout the day. The company has a market cap of $38,588 million and the number of outstanding shares have been calculated to be 105,078,593 shares. The 52-week high of Regeneron Pharmaceuticals (NASDAQ:REGN) is $605.9299 and the 52-week low is $348.96.
Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.